Could Tyme Technologies Inc (NASDAQ:TYME) See a Reversal After More Sellers Came In?

March 14, 2018 - By Michael Collier

 Could Tyme Technologies Inc (NASDAQ:TYME) See a Reversal After More Sellers Came In?

The stock of Tyme Technologies Inc (NASDAQ:TYME) registered an increase of 39.22% in short interest. TYME’s total short interest was 924,700 shares in March as published by FINRA. Its up 39.22% from 664,200 shares, reported previously. With 229,000 shares average volume, it will take short sellers 4 days to cover their TYME’s short positions. The short interest to Tyme Technologies Inc’s float is 3.68%.

The stock decreased 3.31% or $0.08 during the last trading session, reaching $2.34. About 948,378 shares traded or 196.34% up from the average. Tyme Technologies, Inc. (NASDAQ:TYME) has 0.00% since March 14, 2017 and is . It has underperformed by 16.70% the S&P500.

Tyme Technologies, Inc., a clinical-stage pharmaceutical company, focuses on the discovery and development of cancer therapeutics for various oncology indications. The company has market cap of $233.53 million. It is developing SM-88, a combination therapy in Phase II development for prostate cancer. It currently has negative earnings.

More notable recent Tyme Technologies, Inc. (NASDAQ:TYME) news were published by: which released: “Tyme Technologies Announces Offering of Common Stock” on February 26, 2018, also with their article: “Tyme Technologies Announces Closing of Public Offering of Common Stock” published on March 08, 2018, published: “Tyme Technologies Appoints Tommy G. Thompson to Board of Directors” on February 21, 2018. More interesting news about Tyme Technologies, Inc. (NASDAQ:TYME) were released by: and their article: “FDA Acceptance of IND for Tyme to Begin Phase II Trial in Pancreatic Cancer” published on March 14, 2018 as well as‘s news article titled: “Pre-Open Movers 03/14: (RKDA) (RFIL) (TYME) Higher; (EARS) (SILC) (SIG) Lower …” with publication date: March 14, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.